Abstract
4-Aminobutyric acid is an inhibitory neurotransmitter involved in the control of neuronal activity in the mammalian central nervous system. There is considerable direct and indirect evidence that impaired activity of GABAmediated inhibitory synapses may be an important causative factor in experimental and clinical seizure disorders. This review is focused on the recent development of compounds which can influence GABA neurotransmission by affecting the GABA receptors, the plasma-membrane GABA transporters (GATs) and catabolic enzyme GABA-transaminase (GABAT). These compounds have been primarily investigated in relation to epilepsy, but it has also been found that a decrease in GABA neurotransmission appears to be involved in the aetiology of several neurological disorders such as insomnia, spasticity, neuropathic pain, anxiety and other mental disorders.
Keywords: GABA, GABA uptake inhibitors, GABAA receptor ligands, GABAB receptor ligands, GABAC receptor ligands, GABA aminotransferaseinhibitors.
Current Medicinal Chemistry
Title:GABA System as a Target for New Drugs
Volume: 21 Issue: 28
Author(s): P. Kowalczyk and K. Kulig
Affiliation:
Keywords: GABA, GABA uptake inhibitors, GABAA receptor ligands, GABAB receptor ligands, GABAC receptor ligands, GABA aminotransferaseinhibitors.
Abstract: 4-Aminobutyric acid is an inhibitory neurotransmitter involved in the control of neuronal activity in the mammalian central nervous system. There is considerable direct and indirect evidence that impaired activity of GABAmediated inhibitory synapses may be an important causative factor in experimental and clinical seizure disorders. This review is focused on the recent development of compounds which can influence GABA neurotransmission by affecting the GABA receptors, the plasma-membrane GABA transporters (GATs) and catabolic enzyme GABA-transaminase (GABAT). These compounds have been primarily investigated in relation to epilepsy, but it has also been found that a decrease in GABA neurotransmission appears to be involved in the aetiology of several neurological disorders such as insomnia, spasticity, neuropathic pain, anxiety and other mental disorders.
Export Options
About this article
Cite this article as:
Kowalczyk P. and Kulig K., GABA System as a Target for New Drugs, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140601202158
DOI https://dx.doi.org/10.2174/0929867321666140601202158 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Cm38: A New Antimicrobial Peptide Active Against Klebsiella pneumoniae is Homologous to Cn11
Protein & Peptide Letters Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Preface [Hot Topic: Rational Drug Design and The Discovery of the 1,2,3-Triazolines as a Unique Class of Anticonvulsants and Antiischemic Agents (Guest Editor: Pankaja K. Kadaba)]
Current Medicinal Chemistry High Temperature Unfolding Simulations of a Single-stranded DNA i-Motif
Current Physical Chemistry Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Millennium Nutrient N,N-Dimethylglycine (DMG) and its Effectiveness in Autism Spectrum Disorders
Current Medicinal Chemistry Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia
Current Pharmaceutical Design Editorial
Current Pediatric Reviews Editorial (Thematic Issue: Measurements of ABC Transporters at the Blood-Brain Barrier: Novel Methods and Applications)
Current Pharmaceutical Design Long-Term Effects of Hypoxia-Reoxygenation on Thioredoxins in Rat Central Nervous System
Current Pharmaceutical Design Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study
Current Clinical Pharmacology